Cingulate CING
NASDAQ CING
$5.47 +0.14 (+2.62%)
As of: Aug 21, 2026 · 3:31 PM EDT

Cingulate (CING) Cash from Financing Activities (2021 - 2025)

Cingulate's (CING) quarterly Cash from Financing Activities came in at $8.6 million in Q4 2025, up 33.17% YoY from $6.4 million in Q4 2024, and up 348.25% on a QoQ basis from $1.9 million in Q1 2025.

Cingulate (CING) Cash from Financing Activities (2021 - 2025) Analysis & Trends

Cingulate (CING) has 5 years of Cash from Financing Activities data on file, last reported at $8.6 million in Q4 2025.

  • Quarterly Cash from Financing Activities rose 33.17% year-over-year to $8.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30.4 million (down 1.51% YoY) and the FY2025 annual result came in at $16.1 million, down 47.6% from the prior year.
  • Cash from Financing Activities rose to $8.6 million in Q4 2025, from $1.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $19.9 million in Q4 2021 to a low of -$89780.0 in Q4 2022.
  • A 5-year average of $4.6 million and a median of $2.6 million in 2023 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 100.45% — and 2024, when it surged 252377.63%.
  • Tracing CING's Cash from Financing Activities over 5 years: stood at $19.9 million in 2021, then plunged by 100.45% to -$89780.0 in 2022, then jumped by 1008.26% to $815434.0 in 2023, then surged by 690.89% to $6.4 million in 2024, then surged by 33.17% to $8.6 million in 2025.
  • The last three Cash from Financing Activities figures came in at $8.6 million (Q4 2025), $1.9 million (Q1 2025), and $6.4 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.83 Bn 130.98 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.79 Bn 77.79 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 64.95 Bn 59.77 Bn 1.37 Bn -
4 Moderna 58.59 Bn 53.46 Bn 52.00 Mn 14.00 Mn
5 BeOne Medicines 41.93 Bn 36.83 Bn 1.53 Bn -6.05 Mn
6 Alnylam Pharmaceuticals 31.52 Bn 28.21 Bn 992.69 Mn 36.24 Mn
7 BioNTech SE 27.98 Bn 9.58 Bn 668.28 Mn -16.65 Mn
8 Insmed 27.42 Bn 26.26 Bn 358.27 Mn 27.18 Mn
9 Royalty Pharma 27.33 Bn 26.49 Bn - -273.15 Mn
10 Cingulate 72.52 Mn 72.52 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 8.59 Mn
Dec 31, 2025 8.59 Mn
Mar 31, 2025 1.92 Mn
Mar 31, 2025 1.92 Mn
Dec 31, 2024 6.45 Mn
Dec 31, 2024 6.45 Mn
Sep 30, 2024 13.40 Mn
Sep 30, 2024 13.40 Mn
Jun 30, 2024 1.08 Mn
Jun 30, 2024 1.08 Mn
Mar 31, 2024 9.89 Mn
Mar 31, 2024 9.89 Mn
Dec 31, 2023 815,434.00
Dec 31, 2023 815,434.00
Sep 30, 2023 5.93 Mn
Sep 30, 2023 5.93 Mn
Jun 30, 2023 3.21 Mn
Jun 30, 2023 3.21 Mn
Mar 31, 2023 -3,920.00
Mar 31, 2023 -3,920.00